{"id":249803,"date":"2023-09-12T00:00:00","date_gmt":"2023-09-12T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidcv0016-biopharma-peripheral-arterial-disease-epidemiology\/"},"modified":"2026-03-31T10:32:18","modified_gmt":"2026-03-31T10:32:18","slug":"epidcv0016-biopharma-peripheral-arterial-disease-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidcv0016-biopharma-peripheral-arterial-disease-epidemiology-mature-markets\/","title":{"rendered":"Peripheral Arterial Disease &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of peripheral arterial disease (<abbr title=\"peripheral arterial disease\">PAD<\/abbr>) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of <abbr title=\"peripheral arterial disease\">PAD<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report. In addition to forecasting prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"peripheral arterial disease\">PAD<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will changes in the levels of exposure to known risk or protective factors affect the number of people living with <abbr title=\"peripheral arterial disease\">PAD<\/abbr>?<\/li>\n<li>Of all people with <abbr title=\"peripheral arterial disease\">PAD<\/abbr>, how many in each country have been formally diagnosed?<\/li>\n<li>Of all people diagnosed with <abbr title=\"peripheral arterial disease\">PAD<\/abbr>, how many in each country are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"peripheral arterial disease\">PAD<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <span class=\"abbreviation-guard\">MS <\/span>Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts 22 <abbr title=\"peripheral arterial disease\">PAD<\/abbr> patient populations, as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Total prevalent cases of <abbr title=\"peripheral arterial disease\">PAD<\/abbr>.<\/li>\n<li>Total incident cases of <abbr title=\"peripheral arterial disease\">PAD<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"peripheral arterial disease\">PAD<\/abbr>.<\/li>\n<li>Undiagnosed prevalent cases of <abbr title=\"peripheral arterial disease\">PAD<\/abbr>.<\/li>\n<li>Prevalent cases of critical limb ischemia (<abbr title=\"critical limb ischemia\">CLI<\/abbr>) with or without rest pain.<\/li>\n<li>Prevalent cases of undiagnosed <abbr title=\"critical limb ischemia\">CLI<\/abbr> with or without rest pain.<\/li>\n<li><abbr title=\"critical limb ischemia\">CLI<\/abbr> events.<\/li>\n<li>Diagnosed drug-treated prevalent cases of intermittent claudication (<abbr title=\"intermittent claudication\">IC<\/abbr>) without <abbr title=\"critical limb ischemia\">CLI<\/abbr>.<\/li>\n<li>Diagnosed drug-treated prevalent cases of <abbr title=\"critical limb ischemia\">CLI<\/abbr> with or without rest pain.<\/li>\n<li>Diagnosed non-drug-treated prevalent cases of <abbr title=\"critical limb ischemia\">CLI<\/abbr> with or without rest pain.<\/li>\n<li>\u2026 and many more (details available on request).<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-249803","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-cardiovascular","biopharma-therapy-areas-peripheral-arterial-disease","biopharma-product-epidemiology","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249803","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249803\/revisions"}],"predecessor-version":[{"id":281383,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249803\/revisions\/281383"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=249803"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}